Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging

Viruses

Ruchi Chauhan¹  Nerea Zabaleta¹  Dan Li¹  Luk H. Vandenberghe¹  Urja Bhatt¹  Dawid Maciorowski¹  Cheikh Diop¹  Reynette Estelien¹ 

[1] Grousbeck Gene Therapy Center, Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA;

关键词: SARS-CoV-2;    COVID-19;    vaccine;    genetic vaccine;    adeno-associated virus;    AAV;   

DOI  :  10.3390/v14040820

来源: DOAJ

【 摘 要 】

The SARS-CoV-2 pandemic has had a disastrous impact on global health. Although some vaccine candidates have been effective in combating SARS-CoV-2, logistical, economical, and sociological aspects still limit vaccine access globally. Recently, we reported on two room-temperature stable AAV-based COVID-19 vaccines that induced potent and protective immunogenicity following a single injection in murine and primate models. Obesity and old age are associated with increased mortality in COVID-19, as well as reduced immunogenicity and efficacy of vaccines. Here, we investigated the effectiveness of the AAVCOVID vaccine candidates in murine models of obesity and aging. Results demonstrate that obesity did not significantly alter the immunogenicity of either vaccine candidate. In aged mice, vaccine immunogenicity was impaired. These results suggest that AAV-based vaccines may have limitations in older populations and may be equally applicable in obese and non-obese populations.

【 授权许可】

Unknown